SKM9-2 单克隆抗体在唾液酸化 HEG1 上的医学应用，一种用于恶性间皮瘤的新型精准标志物。
Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.
机构信息
Department of Medical Technology & Clinical Engineering, Gunma University of Health and Welfare.
Institute for Genetic Medicine, Hokkaido University.
出版信息
Proc Jpn Acad Ser B Phys Biol Sci. 2023;99(2):39-47. doi: 10.2183/pjab.99.003.
Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleural cavity. Pathologically distinguishing MPM from other pleural lesions is often difficult. We searched for marker antigens to facilitate the pathological diagnosis of MPM and found useful markers for the pathological detection of malignant mesothelioma. Among them, the anti-mesothelioma monoclonal antibody SKM9-2, which was isolated as a clone binding to specimens of MPM (but not to specimens of lung adenocarcinoma) by immunohistochemical screening, showed higher specificity and sensitivity than traditional mesothelioma markers. SKM9-2 recognizes both sialylated O-glycans and peptide sequences in HEG1, and its glycan modifications are specific to mesothelioma. New effective treatments for MPM are needed because the prognosis of patients with MPM is usually poor. SKM9-2 can be used as a seed for next-generation antibody drugs with strong cytotoxic activities. In this review, we have summarized our research on antibody development for MPM diagnosis and treatment.
恶性胸膜间皮瘤（MPM）是一种侵袭性胸膜腔肿瘤。从病理上区分 MPM 和其他胸膜病变通常很困难。我们寻找标记抗原来辅助 MPM 的病理诊断，并发现了用于恶性间皮瘤病理检测的有用标记物。其中，抗间皮瘤单克隆抗体 SKM9-2 通过免疫组化筛选被分离为一种与 MPM 标本（但不与肺腺癌标本）结合的克隆，其特异性和敏感性均高于传统间皮瘤标志物。SKM9-2 识别唾液酸化 O-聚糖和 HEG1 中的肽序列，其糖基化修饰是间皮瘤特异性的。由于 MPM 患者的预后通常较差，因此需要新的有效治疗方法。SKM9-2 可以作为具有强大细胞毒性活性的下一代抗体药物的种子。在这篇综述中，我们总结了我们在 MPM 诊断和治疗方面的抗体开发研究。
Zotero 插件